Ray Therapeutics Announces Upsized and Oversubscribed $125 Million Series B Financing for Vision Restoration Treatments

Funding provides significant capital to support late-stage clinical development and commercial readiness for lead program RTx-015 in Retinitis Pigmentosa, and clinical studies for RTx-021 in Stargardt Disease and Geographic Atrophy